Combines two GHRH-pathway analogs (Tesamorelin, CJC-1295 No-DAC) with a selective ghrelin receptor agonist (Ipamorelin) Each component has independent, well-characterized receptor pharmacology in the peer-reviewed literature No-DAC formulation of CJC-1295 avoids the extended albumin-binding half-life of the DAC-conjugated variant, useful for research designs requiring shorter-acting GHRH exposure Useful reference blend for comparative GHRH receptor / GHS-R1a signaling and pulsatile secretion research Lyophilized format ensures stability and reproducibility across experimental runs Batch and lot identifiers on all labeling for full laboratory documentation compliance Research Background Each component of Tesa-IPA-CJC (No-Dac) has an independent research literature base
Pharmaceutics 17 (2), 210
It's generally recommended to avoid layering GHK-Cu with highly acidic ingredients like L-ascorbic acid (Vitamin C) or potent retinoids in the same session, as this can reduce efficacy or increase irritation
Interestingly, in patients who went on to develop PACS, there were notable reductions in the total EVs levels of the MPs Mitochondrial Open Reading Frame of the 12S rRNA-c (MOTS-c), Voltage-Dependent Anion Channel 1 (VDAC-1), and humanin, along with increased levels of Sterile Alpha and TIR Motif-Containing Protein 1 (SARM-1)
